Dynamics of Antibiotic Resistance of <i>Streptococcus pneumoniae</i> in France: A Pediatric Prospective Nasopharyngeal Carriage Study from 2001 to 2022

• Main Authors: Alexis Rybak (Author), Corinne Levy (Author), Naïm Ouldali (Author), Stéphane Bonacorsi (Author), Stéphane Béchet (Author), Jean-François Delobbe (Author), Christophe Batard (Author), Isabelle Donikian (Author), Marie Goldrey (Author), Jessica Assouline (Author), Robert Cohen (Author), Emmanuelle Varon (Author)
• Format: Book
• Published: MDPI AG, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics12061020; 2079-6382
• Keywords: pneumococcal nasopharyngeal carriage; children; acute otitis media; PCV impact; third-generation pneumococcal conjugate vaccine; next-generation pneumococcal conjugate vaccine; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 12, Iss 6, p 1020 (2023)

Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22, <i>p</i> < 0.001). Five serotypes accounted for 64.4% of the penicillin non-susceptible strains: 11A (17.5%), 35B (14.9%), 15A (13.9%), 15B/C (9.9%) and 19F (8.2%); non-PCV13/PCV15 accounted for <1%, and non-PCV15/PCV20 accounted for 28%. The next generation PCVs, particularly PCV20, may disrupt nasopharyngeal carriage and contribute to decreasing the rate of antibiotic resistance among pneumococci.